Zobrazeno 1 - 10
of 102
pro vyhledávání: '"Karel, Urbánek"'
Publikováno v:
BMJ Open, Vol 13, Iss 7 (2023)
Introduction Colistin is a lipopeptide antibiotic administered as an inactive prodrug—colistin methanesulfonate (CMS). Colistin is a drug with a narrow therapeutic window; the limiting factors are mainly nephrotoxicity and neurotoxicity, dependent
Externí odkaz:
https://doaj.org/article/11ea6d5c3a7e485c8a80a835f9e2a518
Publikováno v:
Antibiotics, Vol 12, Iss 3, p 437 (2023)
The emerging resistance of Gram-negative bacteria is a growing problem worldwide. Together with the financial cost, limited efficacy, and local unavailability of newer antibiotics or their combinations, it has led to the reintroduction of colistin as
Externí odkaz:
https://doaj.org/article/3ef8ee69b09a4556b134d7b2da096729
Autor:
Petr Šantavý, Martin Šíma, Ondřej Zuščich, Vendula Kubíčková, Danica Michaličková, Ondřej Slanař, Karel Urbánek
Publikováno v:
Antibiotics, Vol 11, Iss 11, p 1582 (2022)
The objectives of this study were to develop a population pharmacokinetic model of prophylactically administered cefazolin in patients undergoing cardiac surgery with and without the use of the cardiopulmonary bypass of both existing types—standard
Externí odkaz:
https://doaj.org/article/204a94f8d0c549c8b071938f2f04bdeb
Autor:
Karel Urbánek
Publikováno v:
Klinická farmakologie a farmacie. 37:29-32
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e1469f189f0ab8cc54deb65b0cf00b38
https://doi.org/10.36290/far.2023.005
https://doi.org/10.36290/far.2023.005
Publikováno v:
Klinická farmakologie a farmacie. 37:34-38
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9a1ff48285f86290452e0b40afba412d
https://doi.org/10.36290/far.2023.006
https://doi.org/10.36290/far.2023.006
Autor:
Lenka Doubravská, Miroslava Htoutou Sedláková, Kateřina Fišerová, Vendula Pudová, Karel Urbánek, Jana Petrželová, Magdalena Röderová, Kateřina Langová, Kristýna Mezerová, Pavla Kučová, Karel Axmann, Milan Kolář
Publikováno v:
Antibiotics, Vol 11, Iss 6, p 783 (2022)
This observational retrospective study aimed to analyze whether/how the spectrum of bacterial pathogens and their resistance to antibiotics changed during the worst part of the COVID-19 pandemic (1 November 2020 to 30 April 2021) among intensive care
Externí odkaz:
https://doaj.org/article/aa344e0ffe0440de85573779aaccb8f0
Autor:
Karel Urbánek, Petr Šantavý, Ondřej Zuščich, Vendula Kubíčková, Danica Michaličková, Ondřej Slanař, Martin Šíma
Publikováno v:
Journal of Chemotherapy. :1-9
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1e2050ba4c7a7754687d7a03cc38edf7
https://doi.org/10.1080/1120009x.2023.2170895
https://doi.org/10.1080/1120009x.2023.2170895
Autor:
Karel Urbánek
Publikováno v:
Klinická farmakologie a farmacie. 36:77-80
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bdd377d1ecf511cab0f74094e336d642
https://doi.org/10.36290/far.2022.013
https://doi.org/10.36290/far.2022.013
Publikováno v:
Klinická farmakologie a farmacie. 36:4-7
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::734e1c06c9c4dcf011486d8e993a35f6
https://doi.org/10.36290/far.2022.001
https://doi.org/10.36290/far.2022.001
Autor:
Karel Urbánek, Petra Matalová
Publikováno v:
Klinická farmakologie a farmacie. 34:70-73
Prvni biosimilarni připravek monoklonalni protilatky, zavedený v Evropske unii do klinicke praxe, je infliximab CT‑P13. Dnes mame k dispozici dostatecně robustni data, potvrzujici jeho ucinnost a bezpecnost ve vsech indikacich v lecbě dospělý
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::de602bd24507d039fea6a25258fa0429
https://doi.org/10.36290/far.2020.014
https://doi.org/10.36290/far.2020.014